| |
location
|
Gene name
| metastasis (≧1.30) |
primary tumor
|
m/p ratio
|
|---|
|
1p
|
1p36
|
CDC2L1(p58)
|
1.39
|
1.33
|
1.05
|
|
1p36.33
|
PPKCZ
|
1.52
|
1.24
|
1.23
|
|
1p36.33
|
TP73
|
1.48
|
1.58
|
0.94
|
|
1p36.31
|
D1S214
|
1.76
|
1.21
|
1.45*
|
|
1p36.22
|
D1S1635
|
1.88
|
1.33
|
1.41*
|
|
1p36.13
|
D1S199
|
1.51
|
1.22
|
1.24
|
|
1q
|
1q21
|
WI-5663
|
1.73
|
1.64
|
1.05
|
|
5p
|
5p13
|
DAB2
|
1.87
|
1.55
|
1.21
|
|
8q
|
8q24.11-q24
|
EXT1
|
1.44
|
1.03
|
1.40*
|
|
8q24-qter
|
PTK2
|
1.51
|
1.31
|
1.15
|
|
8q tel
|
SHGC-3110
|
1.40
|
1.29
|
1.09
|
|
8q tel
|
U11829
|
1.35
|
1.16
|
1.16
|
|
9p
|
9p11.2
|
AFM137XA11
|
1.52
|
1.16
|
1.31*
|
|
12p
|
12p tel
|
8 M16/SP6
|
1.49
|
1.08
|
1.38*
|
|
12p tel
|
SHGC-5557
|
1.52
|
1.34
|
1.13
|
|
12p13
|
CCND2
|
1.71
|
1.29
|
1.33*
|
|
12p13.1-p12
|
CDLN1B(p27)
|
1.53
|
1.25
|
1.22
|
|
14q
|
14q32.32
|
AKT1
|
1.68
|
1.51
|
1.11
|
|
14q tel
|
IGH(D14S308)
|
1.51
|
1.16
|
1.30*
|
|
14q tel
|
IGH(SHGC-36156)
|
1.39
|
1.14
|
1.22
|
|
17p
|
17p tel
|
282 M15/SP6
|
1.52
|
1.14
|
1.33*
|
|
17p13.3
|
HIC1
|
1.42
|
1.04
|
1.37*
|
|
17p13.1
|
TP53(p53)
|
1.40
|
1.19
|
1.18
|
|
17p12-17p11.2
|
LLGL1
|
1.67
|
2.06
|
0.81*
|
|
17p12-17p11.2
|
FLI, TOP3A
|
1.60
|
1.88
|
0.85*
|
|
18q
|
18q11.2
|
LAMA3
|
1.73
|
0.87
|
1.99*
|
|
20q
|
20q13.1-q13.2
|
PTPN1
|
1.46
|
1.43
|
1.02
|
|
20q13
|
TNFRSF6B(DCR3)
|
1.50
|
1.23
|
1.22
|
|
21q
|
21q22.3
|
RUNX1(AML1)
|
1.40
|
1.16
|
1.21
|
|
21q22
|
DYRK1A
|
1.37
|
1.13
|
1.21
|
| |
21q tel
|
PCNT2(KEN)
|
1.56
|
1.30
|
1.20
|
- *m/p ratio: the ratio of DCNAs between the primary (p) and metastatic (m) tumor (≧1.30 or ≦0.85). No DCNAs of the loss (≦0.85) was detected in the metastasis.
